Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-06-11Clinical Trial Results: NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC [Phase 2]
Phase 2 trial results of NT-I7 in combination with atezolizumab in previously untreated, PD-L1-expressing locally advanced or metastatic non…
-
CLINICAL_TRIALS trial_result · 2026-06-10Clinical Trial Results: A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy [Phase 3]
Phase 3 study evaluating tiragolumab plus atezolizumab versus placebo plus atezolizumab in completely resected NSCLC after adjuvant platinum…
-
CLINICAL_TRIALS trial_result · 2026-06-09Clinical Trial Results: Precision-exercise-prescription for Lung Cancer Patients Undergoing Surgery: The PEP Study [Phase 3]
Phase 3 trial evaluating precision-exercise prescription for lung cancer patients undergoing surgery has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2026-06-09Clinical Trial Update: Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) [Phase 3]
Phase 3 trial comparing sacituzumab deruxtecan (MK-2870) against pemetrexed plus carboplatin in EGFR-mutated, advanced nonsquamous NSCLC aft…
-
CLINICAL_TRIALS trial_result · 2026-06-09Clinical Trial Update: Precision-exercise-prescription for Lung Cancer Patients Undergoing Surgery: The PEP Study [Phase 3]
Phase 3 trial evaluating precision exercise prescription for lung cancer patients undergoing surgery has completed; results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-06-08Clinical Trial Update: Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer [Phase 3]
Phase 3 trial evaluating JDQ443 versus docetaxel in locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2026-06-08Clinical Trial Update: Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer [Phase 3]
Phase 3 trial comparing photon therapy versus proton therapy for various stages of non-small cell lung cancer is active/not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-06-05Clinical Trial Update: A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer [Phase 3]
Phase 3 trial evaluating osimertinib with or without chemotherapy versus chemotherapy alone as neoadjuvant therapy for EGFRm-positive resect…
-
CLINICAL_TRIALS trial_result · 2026-06-05Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) [Phase 2, Phase 3]
A combined Phase 2/Phase 3 trial evaluating multiple targeted therapies for non-small cell lung cancer is active but not currently recruitin…
-
CLINICAL_TRIALS trial_result · 2026-06-03Clinical Trial Results: A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) [Phase 3]
Phase 3 trial comparing atezolizumab plus tiragolumab versus durvalumab in locally advanced, unresectable stage III non-small cell lung canc…
-
CLINICAL_TRIALS trial_result · 2026-06-03Clinical Trial Results: A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer [Phase 2, Phase 3]
Phase 2/3 trial evaluating tiragolumab with atezolizumab plus pemetrexed and platinum vs pembrolizumab plus pemetrexed and platinum in untre…
-
CLINICAL_TRIALS trial_result · 2026-06-03Clinical Trial Update: A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) [Phase 3]
Phase 3 trial comparing atezolizumab plus tiragolumab versus durvalumab in locally advanced, unresectable stage III non-small cell lung canc…
-
CLINICAL_TRIALS trial_result · 2026-06-03Clinical Trial Update: A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer [Phase 2, Phase 3]
Phase 2/3 trial evaluating tiragolumab with atezolizumab-based PEM/CAR pembrolizumab-based therapy in previously untreated advanced non-squa…
-
CLINICAL_TRIALS trial_result · 2026-06-03Clinical Trial Update: Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC [Phase 3]
Phase 3 trial update evaluating the effect of time-of-day immunochemotherapy on progression-free survival in non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2026-06-02Clinical Trial Update: Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer [Phase 3]
Phase 3 trial comparing JDQ443 with docetaxel in locally advanced or metastatic KRAS G12C mutant non-small cell lung cancer is ongoing/activ…
-
CLINICAL_TRIALS trial_result · 2026-06-02Clinical Trial Update: Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment [Phase 3]
Phase 3 trial evaluating Zongertinib (BI 1810631) for advanced non-small cell lung cancer with HER2 mutations; currently active/not recruiti…
-
CLINICAL_TRIALS trial_result · 2026-06-02Clinical Trial Update: Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) [Phase 3]
Phase 3 trial evaluating Acasunlimab plus Pembrolizumab vs. standard of care Docetaxel in PD-L1-positive non-small cell lung cancer is activ…
-
CLINICAL_TRIALS trial_result · 2026-05-01Clinical Trial Update: Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer [Phase 3]
Phase 3 trial comparing niraparib plus pembrolizumab versus placebo plus pembrolizumab as maintenance in advanced/metastatic non-small cell …
-
CLINICAL_TRIALS trial_result · 2026-04-29Clinical Trial Results: Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer [Phase 3]
Phase 3 trial results evaluating cemiplimab in combination with platinum-based chemotherapy for non-small cell lung cancer have been complet…
-
CLINICAL_TRIALS trial_result · 2026-04-29Clinical Trial Update: Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer [Phase 3]
Phase 3 trial evaluating cemiplimab with platinum-based chemotherapy in non-small cell lung cancer has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2026-04-29Clinical Trial Update: Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment [Phase 3]
Phase 3 trial evaluating Zongertinib (BI 1810631) versus standard treatment for advanced non-small cell lung cancer with HER2 mutations (Lun…
-
CLINICAL_TRIALS trial_result · 2026-04-29Clinical Trial Update: Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer [Phase 2, Phase 3]
Phase 2/3 trial evaluating first-line anti-PD-1/PD-L1 mAb with chemotherapy and bronchoscopy-assisted therapy in advanced non-small cell lun…
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) [Phase 3]
A Phase 3 trial evaluating adagrasib with pembrolizumab and chemotherapy versus placebo with pembrolizumab and chemotherapy in untreated KRA…
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms [Phase 2, Phase 3]
Phase 2/3 pharmacogenomics trial evaluating alectinib with SNPs in patients with non-small cell lung cancer; currently active but not recrui…
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status [Phase 2]
Phase 2 trial update of adagrasib in KRASG12C-mutant non-small cell lung cancer (Stage IV) in elderly or poor performance status patients is…